Amphastar Pharmaceuticals
AMPH
139 hedge funds and large institutions have $531M invested in Amphastar Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 51 increasing their positions, 54 reducing their positions, and 15 closing their positions.
0.9% more ownership
Funds ownership: 57.25% → 58.15% (+0.9%)
3% less capital invested
Capital invested by funds: $550M → $531M (-$19.1M)
6% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 54
5% less funds holding
Funds holding: 146 → 139 (-7)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$8.14M |
| 2 |
Millennium Management
New York
|
+$3.53M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$3.29M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.42M |
| 5 |
Morgan Stanley
New York
|
+$2.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$5.27M |
| 2 |
BlackRock
New York
|
-$1.8M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.59M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.45M |
| 5 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
-$1.17M |
AMPH Hedge Fund Activity: Q3 2021 in Review
139 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q3 2021, worth a combined $531M — down 3.5% from $550M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of AMPH and 10 opened new positions — a net loss of 5 holders — while 54 trimmed existing stakes and 51 added.
The largest buyer was Janus Henderson Group, adding an estimated $8.14M. The largest seller was Goldman Sachs, cutting an estimated $5.27M.
- 139 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q3 2021, down from 146 in Q2 2021.
- Funds reported $531M of Amphastar Pharmaceuticals stock for Q3 2021, down 3.5% quarter-over-quarter.
- 10 funds opened new Amphastar Pharmaceuticals positions in Q3 2021 and 15 closed out, a net change of -5 holders.
- The largest Amphastar Pharmaceuticals buyer in Q3 2021 was Janus Henderson Group, an estimated $8.14M added.
- The largest Amphastar Pharmaceuticals seller in Q3 2021 was Goldman Sachs, an estimated $5.27M sold.
Based on aggregated 13F filings for Q3 2021.